Search

Your search keyword '"Vinelli, F"' showing total 46 results
Start Over Author "Vinelli, F"
46 results on '"Vinelli, F"'

3. HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey

Author

Stroffolini, T., Sagnelli, E., Mele, A., Cottone, C., Almasio, P. L., Traverso, A., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., De Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Daria, S., MINOLI, MARIA LAURA, Gazzaniga, V., Segato, S., ORIOLO, MARIA, Parlotto, A., Ghersetti, M., CAPRA, FRANCESCA, Muratori, R., Sama, C., BOCCIA, SARA, Verdianelli, G., PRATICO', ANTONIO, GRANDI, MARIO, VENTURA, ELISA, Cantoni, F., Vincenti, A., Nerli Alessandro, A., Galeazzi, L., SOLINAS, ALICE, Paroli, M., De Sanctis, G. M., Sereno, S., Clementi, C., Visco Comandino, U., Gallo, A. I., Festi, D., Sabusco, G., Coppola, N., Scolastico, C., Onofrio, M., Imparato, M., Filippini, P., Morisco, F., Liberti, A., BORGIA, GIULIO CESARE, Scarpellino, F., Persico, M., Sagnelli, C., COPPOLA, CLAUDIO, Caserta, L., Elia, A., De Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Frugiuele, P., Ferraro, M., Prestileo, T., Alessandri, A., Russello Maurizio, M., Bellissima, P., Orifici, G., Pisani, G., Angioini, S., Lai, M., Spanneda, M., Stroffolini, T., Sagnelli, E., Mele, A., Cottone, C., Almasio, P.L., Traverso, A., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., De Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Daria, S., Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Praticò, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli Alessandro, A., Galeazzi, L., Solinas, A., Paroli, M., De Sanctis, G.M., Sereno, S., Clementi, C., Visco Comandino, U., Gallo, A.I., Festi, D., Sabusco, G., Coppola, N., Scolastico, C., Onofrio, M., Imparato, M., Filippini, P., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., De Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Frugiuele, P., Ferraro, M., Prestileo, T., Alessandri, A., Russello Maurizio, M., Bellissima, P., Orifici, G., Pisani, G., Angioini, S., Lai, M., and Spanneda, M.

Subjects
Liver Cirrhosis, Adult, Male, HBsAg, medicine.medical_specialty, Cirrhosis, Alcohol Drinking, Liver Cirrhosi, Gallbladder disease, Prevalence, Infectious Disease, Gallstones, Gastroenterology, Liver disease, Risk Factors, Virology, Internal medicine, HBV, medicine, Humans, Cholecystectomy, Risk factor, Aged, Cirrhosi, Hepatology, business.industry, Risk Factor, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, Infectious Diseases, Italy, Gallstone, HCV, Chronic hepatiti, Female, business, Human
Abstract

We assessed the prevalence of gallbladder disease (i.e. gallstones plus cholecystectomy) among patients with liver disease and its association with the severity and aetiology of hepatic injury. Subjects, referred to 79 Italian hospitals, were enrolled in a 6-month period. The independent effect of the severity and aetiology of liver disease on gallstone disease prevalence was assessed by multiple logistic regression analysis. Overall, 4867 subjects tested anti-hepatitis C virus (HCV) positive alone, 839 were hepatitis B virus surface antigen (HBsAg) alone, and 652 had an excessive alcohol intake. The prevalence of gallstone disease was 23.3% in anti-HCV-positive patients, 12.4% in HBsAg positive and 24.2% in subjects reporting excessive alcohol intake, respectively. Gallstone disease prevalence increased by age in each aetiological category. The proportion of patients with gallstone disease who had a cholecystectomy was the highest in HCV+ subjects. After adjusting for the confounding effect of age and body mass index, compared with patients with less severe liver disease, subjects with HCV-related cirrhosis, but not those with alcohol-related cirrhosis, were more likely to have gallstone disease. Subjects with HCV-related cirrhosis (OR 2.13, 95% CI: 1.38-3.26) were more likely to have gallstone disease when compared with those with HBV-related cirrhosis. HCV infection is a risk factor for gallstone disease. In Italy, the high prevalence of HCV infection among cirrhotic patients has important implications, as cholecystectomy in these subjects is associated with high risk of morbidity and mortality. © 2007 The Authors.

Published
2007

4. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

Author

GUARD C, Study Group, Hassanein, T, Bakalos, G, Ahlers, S, Shiffman, Ml, Tallarico, L, Reddy, Kr, Orlandini, A, Ferenci, P, Derbala, M, Coppola, C, Foster, Gr, Basho, J, Shabanaj, G, Harxhi, A, Debzi, N, Afredj, N, Guessab, N, Mahindad, N, Mahiou, H, Aissaoui, M, Al Qameesh, J, Al Ghandoor, Z, Assene, C, Bastens, B, Brixko, C, Cool, M, De Galocsy, C, Delwaide, J, George, C, Laukens, P, Lefebvre, V, Mulkay, Jp, Nevens, F, Servais, B, Van Vlierberghe, H, Horsmans, Y, Henrion, J, Sprengers, D, Michielsen, P, Bourgeois, S, Lasser, L, Langlet, P, Robaeys, G, Martinet, Jp, Warzee, P, Hoste, P, Reynaert, H, Juriens, I, Decaestecker, J, Van Der Meersch, F, Janssens, F, Ahmetagic, S, Verhaz, A, Bevanda, M, Calkic, L, Ibrahimpasic, N, Mesihovic, R, Mello, Ce, Ruiz, Fj, Martins Junior, E, Ferraz, Ml, Silva, G, Mendes, C, Lyra, A, Silva, Mh, Gomide, G, Fernandes, Jc, Pereira, P, Correa, Mc, Teixeira, R, Yousry, A, Hanno, A, Gabr, M, Omar, A, Esmat, G, Karatapanis, S, Nikolopoulou, V, Giannoulis, G, Manolakopoulos, S, Elefsiniotis, I, Drakoulis, C, Dimitroulopoulos, D, Kanatakis, S, Ketikoglou, I, Mimidis, K, Evgenidis, N, Akriviades, E, Vafiadi Zoubouli, I, Tsianos, E, Mela, M, Orfanou, E, Mousoulis, G, Karagiannis, I, Manesis, E, Varga, M, Nemesánszky, E, Fried, K, Schuller, J, Szalay, F, Lengyel, G, Tornai, I, Banyai, T, Lesch, M, Nagy, I, Gervain, J, Tusnadi, A, Schneider, F, Szentgyörgyi, L, Hunyady, B, Vincze, A, Tolvaj, G, Varkonyi, I, Makkai, E, Enyedi, J, Racz, I, Hausinger, P, Váczi, Z, Patai, Á, Ozsvár, Z, Lakner, L, Ribiczey, P, Bhalla, A, Somani, S, Luaia, R, Rao, P, Philip, M, Lawate, P, Nagral, A, Sood, A, Parikh, S, Merat, S, Nassiri Toosi, M, Alavian, Sm, Zali, Mr, Daryani, Ne, Drenaggi, D, Attili, Af, Bandiera, F, Bassi, P, Bellati, G, Bellantani, S, Brunetto, MAURIZIA ROSSANA, Bruno, S, Castelli, F, Castellacci, R, Cattelan, Am, Colombo, M, Craxi, A, D'Angelo, S, Colombo, S, Demelia, L, Di Perri, G, Di Giacomo, A, Ferrari, C, Francisci, D, Casinelli, K, Ganga, R, Costa, C, Mangia, A, Russo, Fp, Matarazzo, F, Mazzella, G, Mazzeo, M, Memoli, M, Montalbano, M, Montalto, G, Pieri, A, Passariello, N, Picciotto, A, Pietrangelo, A, Pirisi, M, Quirino, T, Raimondo, G, Rapaccini, Gl, Rizzardini, G, Rizzetto, M, Russello, M, Sabusco, G, Santantonio, T, Soardo, G, Amedea, A, Verucchi, G, Vinelli, F, Zignego, Al, Zuin, M, Ascione, A, Vinci, M, Pigozzi, Mg, Tundo, P, Saracco, Gm, Amoroso, P, Andreoni, M, Colletta, C, Erne, E, Megna, As, Biglino, A, Chiriaco, P, Foti, G, Spinzi, G, D'Amico, E, Paik, Sw, Ahn, Sh, Lee, Yn, Kim, Y, Yang, J, Han, Sy, Varghese, R, Al Gharabally, A, Askar, H, Sharara, A, Yaghi, C, Rached, Aa, Houmani, Z, Zaarour, F, Dohaibi, A, Ivanovski, L, Joksimovic, N, Abbas, Z, Memon, S, Mohsin, A, Masood, S, Hashmi, Z, Halota, W, Deron, Z, Mazur, W, Flisiak, R, Lipczynski, A, Musialik, J, Piekarska, A, Augustyniak, K, Baka Cwierz, B, Simon, K, Gietka, A, Berak, H, Sieklucki, J, Radowska, D, Szlauer, B, Piekos, T, Olszok, I, Jablkowski, M, Orszulak, G, Warakomska, I, Aleixo, Mj, Valente, C, Macedo, G, Sarmento Castro, R, Roxo, F, Faria, T, Mansinho, K, Velez, J, Ramos, Jp, Guerreiro, H, Alberto, S, Monteverde, C, Serejo, F, Peixe, P, Malhado, J, Curescu, M, Streinu Cercel, A, Caruntu, F, Livia, H, Preotescu, L, Arama, V, Ancuta, I, Gheorghe, L, Stanciu, C, Trifan, A, Acalovschi, M, Andreica, V, Pascu, O, Lencu, M, Sporea, I, Olteanu, D, Ionita Radu, F, Fierbinteanu Braticevici, C, Motoc, A, Silaghi, R, Musat, M, Coman, F, Stan, M, Cijevschi, C, Miftode, E, Delic, D, Jesic, R, Nozic, D, Svorcan, P, Fabri, M, Konstantinovic, L, Pelemis, M, Jankovic, G, Todorovic, Z, Nagorni, A, Kupcova, V, Skladany, L, Szantova, M, Krkoska, D, Jarcuska, P, Schreter, I, Oltman, M, Bocakova, J, Bunganic, I, Holoman, J, Giguere, A, Abdou, A. M., Basic (bio-) Medical Sciences, Gastroenterology, Laboratory of Molecullar and Cellular Therapy, Liver Cell Biology, Michielsen, Peter, GUARD-C Study Group, Graham R. Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K. Rajender Reddy, Ludovico Tallarico, Mitchell L. Shiffman, Silke Ahler, Georgios Bakalo, Tarek Hassanein, GUARD-C Study Group: [.., Davide Drenaggi, Adolfo Francesco Attili, Franco Bandiera, Paolo Bassi, Giorgio Bellati, Stefano Bellantani, Maurizia Brunetto, Savino Bruno, Francesco Castelli, Roberto Castellacci, Anna Maria Cattelan, Massimo Colombo, Antonio Craxi, Salvatore D'angelo, Silvia Colombo, Luigi Demelia, Giovanni Di Perri, Antonio Di Giacomo, Carlo Ferrari, Daniela Francisci, Katia Casinelli, Roberto Ganga, Chiara Costa, Alessandra Mangia, Francesco Paolo Russo, Filippo Matarazzo, Giuseppe Mazzella, Maurizio Mazzeo, Massimo Memoli, Marzia Montalbano, Giuseppe Montalto, Alessandro Pieri, Nicola Passariello, Antonio Picciotto, Antonello Pietrangelo, Mario Pirisi, Tiziana Quirino, Giovanni Raimondo, Gian Ludovico Rapaccini, Giuliano Rizzardini, Mario Rizzetto, Maurizio Russello, Giuseppe Sabusco, Teresa Santantonio, Giorgio Soardo, Alessandri Amedea, Gabriella Verucchi, Francesco Vinelli, Anna Linda Zignego, Massimo Zuin, Antonio Ascione, Maria Vinci, Maria Graziella Pigozzi, Paolo Tundo, Giorgio Maria Saracco, Pietro Amoroso, Massimo Andreoni, Cosimo Colletta, Elke Erne, Angelo Salomone Megna, Alberto Biglino, Piergiorgio Chiriaco, Giuseppe Foti, Giancarlo Spinzi, Emilio D'amico, …], Foster G.R., Coppola C., Derbala M., Ferenci P., Orlandini A., Reddy K.R., Tallarico L., Shiffman M.L., Ahlers S., Bakalos G., Hassanein T., Basho J., Shabanaj G., Harxhi A., Debzi N., Afredj N., Guessab N., Mahindad N., Mahiou H., Aissaoui M., Al Qameesh J., Al Ghandoor Z., Assene C., Bastens B., Brixko C., Cool M., De Galocsy C., Delwaide J., George C., Laukens P., Lefebvre V., Mulkay J.-P., Nevens F., Servais B., Van Vlierberghe H., Horsmans Y., Henrion J., Sprengers D., Michielsen P., Bourgeois S., Lasser L., Langlet P., Robaeys G., Martinet J.-P., Warzee P., Hoste P., Reynaert H., Juriens I., Decaestecker J., Van Der Meersch F., Janssens F., Ahmetagic S., Verhaz A., Bevanda M., Calkic L., Ibrahimpasic N., Mesihovic R., Mello C.E., Ruiz F.J., Junior E.M., Ferraz M.L., Silva G., Mendes C., Lyra A., Silva M.H., Gomide G., Fernandes J.C., Pereira P., Correa M.C., Teixeira R., Yousry A., Hanno A., Gabr M., Omar A., Esmat G., Karatapanis S., Nikolopoulou V., Giannoulis G., Manolakopoulos S., Elefsiniotis I., Drakoulis C., Dimitroulopoulos D., Kanatakis S., Ketikoglou I., Mimidis K., Evgenidis N., Akriviades E., Vafiadi-Zoubouli I., Tsianos E., Mela M., Orfanou E., Mousoulis G., Karagiannis I., Manesis E., Varga M., Nemesanszky E., Fried K., Schuller J., Szalay F., Lengyel G., Tornai I., Banyai T., Lesch M., Nagy I., Gervain J., Tusnadi A., Schneider F., Szentgyorgyi L., Hunyady B., Vincze A., Tolvaj G., Varkonyi I., Makkai E., Enyedi J., Racz I., Hausinger P., Vaczi Z., Patai A., Ozsvar Z., Lakner L., Ribiczey P., Bhalla A., Somani S., Luaia R., Rao P., Philip M., Lawate P., Nagral A., Sood A., Parikh S., Merat S., Nassiri-Toosi M., Alavian S.-M., Zali M.R., Daryani N.E., Drenaggi D., Attili A.F., Bandiera F., Bassi P., Bellati G., Bellantani S., Brunetto M., Bruno S., Castelli F., Castellacci R., Cattelan A.M., Colombo M., Craxi A., D'angelo S., Colombo S., Demelia L., Di Perri G., Di Giacomo A., Ferrari C., Francisci D., Casinelli K., Ganga R., Costa C., Mangia A., Russo F.P., Matarazzo F., Mazzella G., Mazzeo M., Memoli M., Montalbano M., Montalto G., Pieri A., Passariello N., Picciotto A., Pietrangelo A., Pirisi M., Quirino T., Raimondo G., Rapaccini G.L., Rizzardini G., Rizzetto M., Russello M., Sabusco G., Santantonio T., Soardo G., Amedea A., Verucchi G., Vinelli F., Zignego A.L., Zuin M., Ascione A., Vinci M., Pigozzi M.G., Tundo P., Saracco G.M., Amoroso P., Andreoni M., Colletta C., Erne E., Megna A.S., Biglino A., Chiriaco P., Foti G., Spinzi G., D'amico E., Paik S.W., Ahn S.-H., Lee Y.N., Kim Y., Yang J., Han S.Y., Varghese R., Al Gharabally A., Askar H., Sharara A., Yaghi C., Abou Rached A., Houmani Z., Zaarour F., Dohaibi A., Ivanovski L., Joksimovic N., Abbas Z., Memon S., Mohsin A., Masood S., Hashmi Z., Halota W., Deron Z., Mazur W., Flisiak R., Lipczynski A., Musialik J., Piekarska A., Augustyniak K., Baka-Cwierz B., Simon K., Gietka A., Berak H., Sieklucki J., Radowska D., Szlauer B., Piekos T., Olszok I., Jablkowski M., Orszulak G., Warakomska I., Aleixo M.J., Valente C., Macedo G., Sarmento-Castro R., Roxo F., Faria T., Mansinho K., Velez J., Ramos J.P., Guerreiro H., Alberto S., Monteverde C., Serejo F., Peixe P., Malhado J., Curescu M., Streinu-Cercel A., Caruntu F., Livia H., Preotescu L., Arama V., Ancuta I., Gheorghe L., Stanciu C., Trifan A., Acalovschi M., Andreica V., Pascu O., Lencu M., Sporea I., Olteanu D., Ionita-Radu F., Fierbinteanu-Braticevici C., Motoc A., Silaghi R., Musat M., Coman F., Stan M., Cijevschi C., Miftode E., Delic D., Jesic R., Nozic D., Svorcan P., Fabri M., Konstantinovic L., Pelemis M., Jankovic G., Todorovic Z., Nagorni A., Kupcova V., Skladany L., Szantova M., Krkoska D., Jarcuska P., Schreter I., Oltman M., Bocakova J., Bunganic I., Holoman J., Giguere A., Abdou A.M.S., UCL - SSS/IREC-Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN-Pôle d'Hépato-gastro-entérologie, and UCL - (SLuc) Service de gastro-entérologie

Subjects
Genetics and Molecular Biology (all), Male, Chronic Hepatitis, Hepacivirus, Ribavirin/adverse effects, Asthenia/chemically induced, Polyethylene Glycol, Biochemistry, Polyethylene Glycols, Body Mass Index, Chronic Liver Disease, 0302 clinical medicine, Neutropenia/chemically induced, Interferon-alpha/adverse effects, Medicine, Chronic, lcsh:Science, Liver Diseases, virus diseases, Antiviral Agents/adverse effects, Cohort, Science & Technology - Other Topics, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Cohort study, Human, medicine.medical_specialty, Alpha interferon, Gastroenterology and Hepatology, Antiviral Agents, Microbiology, Dose-Response Relationship, 03 medical and health sciences, Pharmacotherapy, Hepatitis C, Chronic/drug therapy, Dose Prediction Methods, Drug Therapy, Anemia/chemically induced, Humans, Hemoglobin, Aged, Medicine and health sciences, Biochemistry, Genetics and Molecular Biology (all), Hepaciviru, Science & Technology, Dose-Response Relationship, Drug, Flaviviruses, lcsh:R, Organisms, Biology and Life Sciences, Proteins, medicine.disease, digestive system diseases, chemistry, Agricultural and Biological Sciences (all), Withholding Treatment, Asthenia, Immunology, Proportional Hazards Model, lcsh:Q, Human medicine, RNA viruses, Physiology, lcsh:Medicine, Peginterferon-alfa, Polyethylene Glycols/adverse effects, Adult, Anemia, Cohort Studies, Female, Hepatitis C, Chronic, Host-Pathogen Interactions, Interferon-alpha, Middle Aged, Neutropenia, Outcome Assessment (Health Care), Proportional Hazards Models, RNA, Viral, Recombinant Proteins, Ribavirin, Medicine (all), chemistry.chemical_compound, Outcome Assessment, Health Care, Medicine and Health Sciences, 030212 general & internal medicine, Viral, Pathology and laboratory medicine, Multidisciplinary, biology, Hepatitis C virus, Pharmaceutics, Hepatitis C, Hematology, Recombinant Protein, Outcome Assessment (Health Care)/methods, Medical microbiology, Host-Pathogen Interaction, Multidisciplinary Sciences, Physiological Parameters, Research Design, Combination, Viruses, Drug, Pathogens, Host-Pathogen Interactions/drug effects, Research Article, Clinical Research Design, Research and Analysis Methods, Internal medicine, Recombinant Proteins/adverse effects, RNA, Viral/blood, Antiviral Agent, business.industry, Body Weight, Hepacivirus/drug effects, Viral pathogens, biology.organism_classification, Hepatitis viruses, Microbial pathogens, RNA, Adverse Events, Cohort Studie, business
Abstract

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA

Published
2015

6. Chronic hepatitis B in Italy: New features of an old disease - Approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection

Author

Sagnelli, Evangelista, Stroffolini, Tommaso, Mele, Alfonso, Imparato, Michele, Almasio, Piero L., Traverso, A., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., De Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Sacchini, D., Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Praticò, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli Alessandro, A., Galeazzi, L., Solinas, A., Paroli, M., De Sanctis, G. M., Sereno, S., Clementi, C., Visco Comandino, U., Gallo, A. I., Festi, D., Sabusco, G., Coppola, N., Scolastico, C., Onofrio, M., Filippini, P., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., De Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Frugiuele, P., Ferraro, M., Prestileo, T., Alessandri, A., Russello, M., Bellissima, P., Orifici, G., Pisani, G., Angioini, S., Lai, M., Spanneda, M., Sagnelli, Evangelista, Stroffolini, Tommaso, Mele, Alfonso, Imparato, Michele, Almasio, Piero L., Traverso, A., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., De Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Sacchini, D., Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Praticò, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli Alessandro, A., Galeazzi, L., Solinas, A., Paroli, M., De Sanctis, G.M., Sereno, S., Clementi, C., Visco Comandino, U., Gallo, A.I., Festi, D., Sabusco, G., Coppola, N., Scolastico, C., Onofrio, M., Filippini, P., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., De Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Frugiuele, P., Ferraro, M., Prestileo, T., Alessandri, A., Russello, M., Bellissima, P., Orifici, G., Pisani, G., Angioini, S., Lai, M., and Spanneda, M.

Subjects
Liver Cirrhosis, Adult, Male, Microbiology (medical), medicine.medical_specialty, Cirrhosis, Adolescent, Hepatitis D, Chronic, Hepatitis C virus, Hepacivirus, Liver Cirrhosi, medicine.disease_cause, Gastroenterology, Virus, Flaviviridae, Hepatitis B, Chronic, Seroepidemiologic Studies, Internal medicine, medicine, Humans, Hepatitis B e Antigens, Aged, Aged, 80 and over, Cross-Sectional Studie, Hepaciviru, biology, business.industry, Seroepidemiologic Studie, Hepatitis Delta Viru, Hepatitis B, Middle Aged, medicine.disease, biology.organism_classification, Hepatitis D, Virology, Alcoholism, Cross-Sectional Studies, Infectious Diseases, Italy, Disease Progression, Female, Hepatitis B e Antigen, Hepatitis D virus, Hepatitis Delta Virus, business, Human
Abstract

We evaluated 1336 hepatitis B surface antigen-positive subjects consecutively observed in 79 Italian hospitals over a 6-month period. The proportion of hepatitis B e antigen-negative cases was 86.4%, that of patients coinfected with hepatitis D virus was 9.7%, and the rate of patients coinfected with hepatitis C virus was 16.8%. Multiple logistic regression analysis showed that age >49 years, alcohol abuse, and anti-hepatitis D virus and anti-hepatitis C virus positivity were independent predictors of progression to liver cirrhosis. © 2007 by the Infectious Diseases Society of America. All rights reserved.

Published
2008

7. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases

Author

Sagnelli, Evangelista, Stroffolini, Tommaso, Mele, Alfonso, Almasio, Piero, Coppola, Nicola, Ferrigno, Luigina, Scolastico, Carlo, Onofrio, Mirella, Imparato, Michele, Filippini, Pietro, Traverso, A., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., De Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Sacchini, D., Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Praticò, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli, A., Galeazzi, L., Solinas, A., Paroli, M., De Sanctis, G. M., Sereno, S., Clementi, C., Comandino, U. Visco, Gallo, A. I., Festi, D., Sabusco, G., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., De Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Furgiuele, P. L., Ferraro, M., Prestileo, T., Alessandri, A., Russello, M., Bellissima, P., Orifici, G., Pisani, G., Angioni, S., Lai, M., Spanneda, M., SAGNELLI E, STROFFOLINI T, MELE A, ALMASIO PL, COPPOLA N, FERRIGNO L, SCOLASTICO C, ONOFRIO M, IMPARATO M, FILIPPINI P, Sagnelli, Evangelista, Stroffolini, Tommaso, Mele, Alfonso, Almasio, Piero, Coppola, Nicola, Ferrigno, Luigina, Scolastico, Carlo, Onofrio, Mirella, Imparato, Michele, Filippini, Pietro, Traverso, A., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., De Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Sacchini, D., Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Praticò, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli, A., Galeazzi, L., Solinas, A., Paroli, M., De Sanctis, G.M., Sereno, S., Clementi, C., Comandino, U. Visco, Gallo, A.I., Festi, D., Sabusco, G., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., De Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Furgiuele, P.L., Ferraro, M., Prestileo, T., Alessandri, A., Russello, M., Bellissima, P., Orifici, G., Pisani, G., Angioni, S., Lai, M., and Spanneda, M.

Subjects
Adult, Liver Cirrhosis, Male, Hepatitis B virus, HBsAg, Carcinoma, Hepatocellular, Cirrhosis, alcohol abuse, Hepatitis C virus, Hepacivirus, Chronic liver disease, medicine.disease_cause, Risk Factors, Virology, Prevalence, medicine, HBV, Humans, Aged, business.industry, Incidence, Liver Diseases, Liver Neoplasms, Hepatitis C, Middle Aged, Hepatitis B, medicine.disease, Alcoholism, Infectious Diseases, Italy, Hepatocellular carcinoma, Chronic Disease, HCV, Female, Viral hepatitis, business
Abstract

Knowledge of the current epidemiology of chronic liver disease in Italy is mostly obsolete and fragmentary for the lack of up-to-date consistent data. In 2001, a 6-month prevalence study was undertaken in 79 hospitals to assess the characteristics of chronic liver disease in Italy. Both prevalent and incident cases were enrolled. A total of 9,997 patients were recruited, of whom 939 (9.4%) had normal liver biochemistry, 6,210 (62.1%) had chronic hepatitis, 1,940 (19.4%) had liver cirrhosis, and 341 (3.4%) had hepatocellular carcinoma (HCC). In 567 patients (5.7%) the diagnosis was not established. Hepatitis C virus (HCV) was found in 69.9% of the patients and was the only etiological factor in 56.3% of all the patients. Hepatitis B surface antigen (HBsAg) was present in the serum of 13.4% of the cases (in 10% it was the only etiological factor). A history of alcohol abuse was found in 23% of the cases (9.4% without viral infection). The prevalence of HCV-related cases was significantly lower in incident than in prevalent cases (44.9% vs. 59.9%, P < 0.0001), while the proportion of patients with alcohol abuse was much higher in incident than in prevalent cases (18.1% vs. 6.6%, P < 0.0001). These findings indicate that nearly one quarter of patients with chronic liver diseases in Italy have a severe disease such as liver cirrhosis and HCC represents a not negligible burden for the national health system. Hepatitis B fell in importance as an etiological factor. Hepatitis C is the important pathogenic factor for chronic liver disease in Italy. However, a comparison between the prevalent and incident cases suggests that in future HCV infection will also play a progressively decreasing role, in part as a consequence of treatment. © 2005 Wiley-Liss, Inc.

Published
2005

8. The aetiology of chronic hepatitis in Italy: results from a multicentre national study

Author

Stroffolini, T., Sagnelli, E., Mele, A., Craxi, A., Almasio, P., Traverso, A., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., De Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Daria, Sacchini, Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Pratico, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli Alessandro, A., Galeazzi, L., Solinas, A., Paroli, Marino, De Sanctis, G. M., Sereno, S., Clementi, C., Visco Comandino, U., Gallo, A. I., Festi, D., Sabusco, G., Coppola, N., Scolastico, C., Onofrio, M., Imparato, M., Filippini, P., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., De Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Frigiuele, P., Ferraro, M., Prestileo, T., Alessandri, A., Russello Maurizio, M., Bellissima, P., Orifici, G., Pisani, G., Angioini, S., Lai, M., Spanneda, M., Stroffolini, T, Sagnelli, E, Mele, A, Crax, A, Almasio, P, Coppola, Nicola, Italian Hospitals Collaborating, Group, Filippini, Pietro, Sagnelli, Caterina, STROFFOLINI T, SAGNELLI E, MELE A, CRAXI A, ALMASIO PL, ITALIAN HOSPITALS, COLLABORATING GROUP, Stroffolini, T., Sagnelli, E., Mele, A., Craxì, A., Almasio, P., Traverso, A., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., De Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Daria, S., Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Praticò, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli Alessandro, A., Galeazzi, L., Solinas, A., Paroli, M., De Sanctis, G.M., Sereno, S., Clementi, C., Visco Comandino, U., Gallo, A.I., Festi, D., Sabusco, G., Coppola, N., Scolastico, C., Onofrio, M., Imparato, M., Filippini, P., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., De Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Frigiuele, P., Ferraro, M., Prestileo, T., Alessandri, A., Russello Maurizio, M., Bellissima, P., Orifici, G., Pisani, G., Angioini, S., Lai, M., and Spanneda, M.

Subjects
Adult, Male, medicine.medical_specialty, HBsAg, Hepatitis D, Chronic, Epidemiology, Hepatitis C virus, Autoimmune hepatitis, medicine.disease_cause, Autoimmune Diseases, Hepatitis B, Chronic, Internal medicine, medicine, Prevalence, Humans, Hepatitis B virus, Hepatology, business.industry, Gastroenterology, Hepatitis C, Hepatitis B, Hepatitis C, Chronic, Middle Aged, medicine.disease, Hepatitis D, HBeAg, Italy, Immunology, Chronic hepatiti, Female, chronic hepatitis, epidemiology, italy, business
Abstract

Background: No recent national-level data on the aetiology of chronic hepatitis are available in Italy. Aim: To evaluate the current aetiology of chronic hepatitis in Italy. Patients: A total of 6210 chronic hepatitis patients (both prevalence and incident cases) consecutively admitted to 79 hospitals located throughout Italy were enrolled over a 6-month period in 2001. The hospitals were randomly selected through systematic cluster sampling. Results: The main agent associated with chronic hepatitis was hepatitis C virus, which was found in 76.5% of the patients (in 62.6% it was the only aetiologic factor). Hepatitis B surface antigen was present in the serum of 12.2% of the cases (in 9.2% it was the only aetiologic factor). Hepatitis B e antigen and hepatitis Delta were detected in 16.6% and 7.0%, respectively, of hepatitis B surface antigen-positive patients. A history of alcohol abuse was found in 19.2% of the cases (5.5% without viral infection). Autoimmune hepatitis and inborn metabolic disorders were extremely rare. The prevalence of hepatitis C virus-related cases was significantly lower in incident cases, compared to prevalent cases (55.1% versus 65.0%; p < 0.01). The mean alanine aminotransferase level was significantly higher in hepatitis B surface antigen-positive patients, compared to hepatitis B surface antigen-negative patients. The histology was less severe in non-viral-related cases. Conclusions: Hepatitis C virus is the most important pathogenic factor for chronic hepatitis in Italy; however, the comparison between prevalent and incident cases suggests that this infection will play a less important role in the future. A comparison with previous reports shows that both hepatitis B virus-related and hepatitis Delta virus-related cases are decreasing. © 2004 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Published
2004

9. The Italian ENTAS cohort study: Entecavir effectiveness in naïve and treatment experienced patients with chronic hepatitis B

Author

Porro, E., primary, Di Leo, A., additional, Marzano, A., additional, Brancaccio, G., additional, Maimone, S., additional, Fasano, M., additional, Grasso, A., additional, Bronte, F., additional, Fagiuoli, S., additional, Santantonio, T., additional, Morisco, F., additional, Petrelli, E., additional, Surace, G., additional, Labbadia, G., additional, Badia, L., additional, Niro, G.A., additional, Vinci, M., additional, Montineri, A., additional, Vinelli, F., additional, Massari, M., additional, Nosotti, L., additional, Galati, G., additional, and Missale, G., additional

Published
2015
Full Text
View/download PDF

10. Liver stiffness, a non-invasive marker of liver disease: a core study group report

Author

Bonino, F, Arena, U, Brunetto, Mr, Coco, B, Fraquelli, M, Oliveri, F, Pinzani, M, Prati, D, Rigamonti, C, Vizzuti, F, Collaborators: Balocco M, Liver Stiffness Study Group 'Elastica' of the Italian Association for the Study of the Liver., Forni, G, Bottelli, R, Bruno, R, Filice, C, Bruno, S, Cammà, C, Craxì, A, Colletta, C, Colombatto, P, Colombo, M, Fatuzzo, F, Larocca, L, Montineri, A, Festi, D, Colecchia, A, Grasso, A, Maida, I, Mazzotta, F, Marino, N, Blanc, P, Puoti, M, Quartini, M, Sacchini, D, Vinelli, F., Craxi, A, Bonino, F, Arena, U, Brunetto, MR, Coco, B, Fraquelli, M, Oliveri, F, Pinzani, M, Prati, D, Rigamonti, C, Vizzuti, F, and Liver Stiffness Study Group 'Elastica' of the Italian Association for the Study of the Liver

Subjects
Pharmacology, Liver Cirrhosis, medicine.medical_specialty, Core (anatomy), business.industry, Non invasive, Hepatitis B, medicine.disease, Gastroenterology, Clinical Practice, liver stiffness, Liver disease, Infectious Diseases, Liver, Liver stiffness, Internal medicine, medicine, Elasticity Imaging Techniques, Pharmacology (medical), Transient elastography, business, Liver pathology, Biomarkers
Abstract

The ability to evaluate liver stiffness non-invasively in clinical practice by measuring transient elastography using FibroScan® has resulted in considerable interest and enthusiasm. A core study group, organized by the Italian Association for the Study of the Liver, has assessed the usefulness of FibroScan® in the diagnosis and management of liver disease in clinical practice. The group concluded that FibroScan® is a valuable, non-invasive technique and have developed a consensus report form for registering transient elastography results. In this article, we report the findings of the study group.

Published
2010

11. HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey. J Viral Hepat

Author

Stroffolini, T., Sagnelli, E., Mele, A., Cottone, C., Almasio, Pl, Traverso, ., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Sacchini, D., Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Praticò, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli Alessandro, A., Galeazzi, L., Solinas, A., Marino PAROLI, Sanctis, G. M., Sereno, S., Clementi, C., Visco Comandino, U., Gallo, A. I., Sabusco, D. G., Coppola, N., Scolastico, C., Onofrio, M., Filippini, P., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Frugiuele, P., Ferraro, M., Prestileo, T., Alessandri, A., Russello, M., Bellissima, P., Orifici, G., Pisani, G., Angioini, S., Lai, M., and Spanneda, M.

Published
2007

12. Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases

Author

Stroffolini, T., Sagnelli, E., Mariano, A., Craxí, A., Almasio, P., Traverso, ., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Sacchini, D., Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Praticò, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli Alessandro, A., Galeazzi, L., Solinas, A., Marino PAROLI, Sanctis, G. M., Sereno, S., Clementi, C., Visco Comandino, U., Gallo, A. I., Sabusco, D. G., Coppola, N., Scolastico, C., Onofrio, M., Filippini, P., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Frugiuele, P., Ferraro, M., Prestileo, T., Alessandri, Nicola, Russello, M., Bellissima, P., Orifici, G., Pisani, G., Angioini, S., Lai, M., and Spanneda, M.

Published
2006

13. P1047 ENTECAVIR EFFECTIVENESS IN NAIVE AND NUC EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B AND LIVER CIRRHOSIS: INTERIM ANALYSIS OF THE ITALIAN ENTAS COHORT STUDY

Author

Porro, E., primary, Di Leo, A., additional, Marzano, A., additional, Brancaccio, G., additional, Maimone, S., additional, Fasano, M., additional, Grasso, A., additional, Bronte, F., additional, Fagiuoli, S., additional, Santantonio, T., additional, Morisco, F., additional, Petrelli, E., additional, Svegliati Baroni, G., additional, Labbadia, G., additional, Badia, L., additional, Niro, G.A., additional, Vinci, M., additional, Montineri, A., additional, Vinelli, F., additional, Massari, M., additional, Nosotti, L., additional, Galati, G., additional, and Missale, G., additional

Published
2014
Full Text
View/download PDF

14. Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B

Author

Porro, E., primary, Di Leo, A., additional, Marzano, A., additional, Brancaccio, G., additional, Maimone, S., additional, Fasano, M., additional, Grasso, A., additional, Bronte, F., additional, Fagiuoli, S., additional, Santantonio, T., additional, Morisco, F., additional, Petrelli, E., additional, Svegliati Baroni, G., additional, Labbadia, G., additional, Badia, L., additional, Niro, G.A., additional, Vinci, M., additional, Montineri, A., additional, Vinelli, F., additional, Massari, M., additional, Nosotti, L., additional, Galati, G., additional, and Missale, G., additional

Published
2014
Full Text
View/download PDF

16. 764 ENTECAVIR EFFECTIVENESS IN DAILY CLINICAL PRACTICE, INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B

Author

Giuberti, T., primary, Fasano, M., additional, Brancaccio, G., additional, Santantonio, T., additional, Grasso, A., additional, Marzano, A., additional, Bronte, F., additional, Maimone, S., additional, Fagiuoli, S., additional, Caporaso, N., additional, Petrelli, E., additional, Svegliati Baroni, G., additional, Labbadia, G., additional, Verucchi, G., additional, Niro, G.A., additional, Pinzello, G.B., additional, Montineri, A., additional, Vinelli, F., additional, Massari, M., additional, Nosotti, L., additional, Picardi, A., additional, and Missale, G., additional

Published
2013
Full Text
View/download PDF

17. 763 ENTECAVIR EFFECT ON LIVER FUNCTION IN FIELD PRACTICE: INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B

Author

Alfieri, A., primary, Fasano, M., additional, Brancaccio, G., additional, Santantonio, T., additional, Malfatti, F., additional, Marzano, A., additional, Bronte, F., additional, Caccamo, G., additional, Fagiuoli, S., additional, Morisco, F., additional, Petrelli, E., additional, Svegliati Baroni, G., additional, Labbadia, G., additional, Verucchi, G., additional, Ippolito, A.M., additional, Pinzello, G.B., additional, Montineri, A., additional, Vinelli, F., additional, Massari, M., additional, Nosotti, L., additional, Galati, G., additional, and Missale, G., additional

Published
2013
Full Text
View/download PDF

18. T-14 Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B

Author

Giuberti, T., primary, Fasano, M., additional, Brancaccio, G., additional, Santantonio, T., additional, Grasso, A., additional, Marzano, A., additional, Bronte, F., additional, Maimone, S., additional, Fagiuoli, S., additional, Caporaso, N., additional, Petrelli, E., additional, Svegliati Baroni, G., additional, Labbadia, G., additional, Verucchi, G., additional, Niro, G.A., additional, Pinzello, G.B., additional, Montineri, A., additional, Vinelli, F., additional, Massari, M., additional, Nosotti, L., additional, Picardi, A., additional, and Missale, G., additional

Published
2013
Full Text
View/download PDF

19. T-15 Interim analysis of the Italian Master-Entas cohort study: entecavir can improve liver function in patients with chronic hepatitis B and liver cirrhosis

Author

Alfieri, A., primary, Fasano, M., additional, Brancaccio, G., additional, Santantonio, T., additional, Malfatti, F., additional, Marzano, A., additional, Bronte, F., additional, Caccamo, G., additional, Fagiuoli, S., additional, Morisco, F., additional, Petrelli, E., additional, Svegliati Baroni, G., additional, Labbadia, G., additional, Verucchi, G., additional, Ippolito, A.M., additional, Pinzello, G.B., additional, Montineri, A., additional, Vinelli, F., additional, Massari, M., additional, Nosotti, L., additional, Galati, G., additional, and Missale, G., additional

Published
2013
Full Text
View/download PDF

21. 8 FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION

Author

Mangia, A., primary, Minerva, N., additional, Bacca, D., additional, Cozzolongo, R., additional, Agostinacchio, E., additional, Sogari, F., additional, Vinelli, F., additional, Scotto, G., additional, Ricci, G.L., additional, Romano, M., additional, Carretta, V., additional, Petruzzellis, D., additional, Piazzolla, V., additional, Spirito, F., additional, and Andriulli, A., additional

Published
2008
Full Text
View/download PDF

29. ENTECAVIR EFFECTIVENESS IN DAILY CLINICAL PRACTICE, INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B

Author

Giuberti, T., Fasano, M., Brancaccio, G., Santantonio, T., Grasso, A., Marzano, A., Fabrizio Bronte, Maimone, S., Fagiuoli, S., Caporaso, N., Petrelli, E., Baroni, G. Svegliati, Labbadia, G., Verucchi, G., Niro, G. A., Pinzello, G. B., Montineri, A., Vinelli, F., Massari, M., Nosotti, L., Picardi, A., Missale, G., and Master-Entas Study, Grp

30. Chronic hepatitis B in Italy: new features of an old disease--approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection

Author

Sagnelli, E., Stroffolini, T., Mele, A., Imparato, M., Almasio, Pl, Traverso, ., Arrigoni, A., Torchio, M., Garbagnoli, P., Del Mastro, B., Romano, P., Vanni, R., Brusita, D., Meucci, P., Cassola, G., Borzio, M., Bellobuono, A., Bona, A., Re, T., Del Poggio, P., Baisini, O., Colombo, A., Attolini, C., Sacchini, D., Minoli, L., Gazzaniga, V., Segato, S., Oriolo, M., Parlotto, A., Ghersetti, M., Capra, F., Muratori, R., Sama, C., Boccia, S., Verdianelli, G., Praticò, A., Grandi, M., Ventura, E., Cantoni, F., Vincenti, A., Nerli Alessandro, A., Galeazzi, L., Solinas, A., Marino PAROLI, Sanctis, G. M., Sereno, S., Clementi, C., Visco Comandino, U., Gallo, A. I., Sabusco, D. G., Coppola, N., Scolastico, C., Onofrio, M., Filippini, P., Morisco, F., Liberti, A., Borgia, G., Scarpellino, F., Persico, M., Sagnelli, C., Coppola, C., Caserta, L., Elia, A., Vita, G., Lanzotti, A., Pizzolante, L., Messina, V., Fiore, G., Agostinacchio, E., Santantonio, T., Mazzola, M., Vinelli, F., Campagna, A., Cataldini, S., Monelli, I., Lascaro, M., Polimeri, N., Frugiuele, P., Ferraro, M., Prestileo, T., Alessandri, A., Russello, M., Bellissima, P., Orifici, G., Pisani, G., Angioini, S., Lai, M., and Spanneda, M.

31. Re-treatment of patients with chronic hepatitis C in clinical practice: Results of a multicenter retrospective survey,Ritrattamento dei pazienti con epatite cronica da HCV nella pratica clinica: Risultati di uno studio multicentrico retrospettivo

Author

Pizzigallo, E., Toccaceli, F., Vecchiet, J., Di Girolamo, A., Sereno, S., Koch, M., Capurso, L., Lagiii, V., Laghi, V., Santoro, L., Servillo, F., Brillanti, S., Stellini, R., Allegri, R., Filippis, V., Arbore, S., Zammataro, M., Russello, M., Santis, S., Martino, G., Frugiuele, P. L., Spagnuolo, V., Milani, S., Pignalosa, P., Vinelli, F., Cela, E. M., Conca, V., Mesiti, S., Castellacci, R., Mignani, E., Artioli, S., Luca Andrioli, E. P., Maci, A. M., Luca, M., Picciotto, F. P., Marcello Persico, Palmentieri, B., Esposito, P., Iuliano, D., Tarantino, G., Conca, P., Piccinino, F., Scolastico, C., Colletta, C., Montalto, G., Vuturo, O., Tripi, S., Bonfissuto, G., Petrelli, E., Stoppini, L., Marenco, G., Azzola, E., Sabatella, C., Stefano, G., Ceglia, T., Fornaciari, G., Castagnetti, E., Armignacco, O., Barlattani, A., Veglio, V., Bonasso, M., Araneo, A., Carretta, V., Bertuccio, S., Brogna, M., Starnini, G., Foresti, F., and Scaduti, S.

32. Re-treatment of patients with chronic hepatitis C in clinical practice: Results of a multicenter retrospective survey | Ritrattamento dei pazienti con epatite cronica da HCV nella pratica clinica: Risultati di uno studio multicentrico retrospettivo

Author

Pizzigallo, E., Toccaceli, F., Vecchiet, J., Di Girolamo, A., Sereno, S., Koch, M., Capurso, L., Lagiii, V., Laghi, V., Santoro, L., Servillo, F., Brillanti, S., Stellini, R., Allegri, R., Filippis, V., Arbore, S., Zammataro, M., Russello, M., Santis, S., Martino, G., Frugiuele, P. L., Spagnuolo, V., Milani, S., Pignalosa, P., Vinelli, F., Cela, E. M., Conca, V., Mesiti, S., Castellacci, R., Mignani, E., Artioli, S., Luca Andrioli, E. P., Maci, A. M., Luca, M., Picciotto, F. P., Persico, M., Palmentieri, B., Esposito, P., Iuliano, D., Tarantino, G., Conca, P., Piccinino, F., Scolastico, C., Colletta, C., Giuseppe MONTALTO, Vuturo, O., Tripi, S., Bonfissuto, G., Petrelli, E., Stoppini, L., Marenco, G., Azzola, E., Sabatella, C., Stefano, G., Ceglia, T., Fornaciari, G., Castagnetti, E., Armignacco, O., Barlattani, A., Veglio, V., Bonasso, M., Araneo, A., Carretta, V., Bertuccio, S., Brogna, M., Starnini, G., Foresti, F., and Scaduti, S.

40. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

Author

Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A, Mangia, Alessandra, Santoro, Rosanna, Minerva, Nicola, Ricci, Giovanni L, and Carretta, Vito

Abstract

Background: We hypothesized that in patients with hepatitis C virus (HCV) genotype 2 or 3 in whom HCV RNA is not detectable after 4 weeks of therapy, 12 weeks of treatment is as effective as 24 weeks.Methods: A total of 283 patients were randomly assigned to a standard 24-week regimen of peginterferon alfa-2b at a dose of 1.0 mug per kilogram weekly plus ribavirin at a dose of 1000 mg or 1200 mg daily, on the basis of body weight. Of these, 70 patients were assigned to the 24-week regimen (standard-duration group) and 213 patients to a variable regimen (variable-duration group) of 12 or 24 weeks, depending on whether tests for HCV RNA were negative or positive at week 4. The primary end point was HCV that was not detectable by polymerase-chain-reaction (PCR) assay 24 weeks after the completion of therapy.Results: In the standard-duration group, 45 (64 percent) patients had HCV that was not detectable by PCR assay at week 4, as compared with 133 (62 percent) in the variable-duration group (difference [the rate in the standard-duration group minus that in the variable-duration group], 2 percent; 95 percent confidence interval, -11 to 15 percent). Fifty-three patients (76 percent) in the standard-duration group and 164 patients (77 percent) in the variable-duration group had a sustained virologic response (difference, -1 percent; 95 percent confidence interval, -13 to 10 percent). Fewer patients in the variable-duration group receiving the 12-week regimen had adverse events and withdrew than in the group receiving the 24-week regimen (P=0.045). The rate of relapse (defined as HCV not detectable at the end of treatment but detectable at the end of follow-up) was 3.6 percent in the standard-duration group and 8.9 percent in the variable-duration group (P=0.16). Overall, the rate of sustained virologic response was 80 percent among patients with HCV genotype 2 and 66 percent among those with genotype 3 (P<0.001).Conclusions: A shorter course of therapy over 12 weeks with peginterferon alfa-2b and ribavirin is as effective as a 24-week course for patients with HCV genotype 2 or 3 who have a response to treatment at 4 weeks. [ABSTRACT FROM AUTHOR]

Published
2005

41. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial

Author

Giuseppe Cristofaro, Giuseppe Montalto, D. Bacca, Francesco Vinelli, Raffaele Cozzolongo, G.L. Ricci, Angelo Andriulli, Leonardo Mottola, Mario R. Romano, Nicola Minerva, Fulvio Spirito, Gaetano Scotto, Vito Carretta, Alessandra Mangia, MANGIA A, MINERVA N, BACCA D, COZZOLONGO R, RICCI GL, CARRETTA V, VINELLI F, SCOTTO G, MONTALTO G, ROMANO M, CRISTOFARO G, MOTTOLE L, SPIRITO F, and ANDRIULLI A

Subjects
Adult, Male, medicine.medical_specialty, Genotype, Hepatitis C virus, Alpha interferon, Hepacivirus, Interferon alpha-2, medicine.disease_cause, Antiviral Agents, Gastroenterology, Drug Administration Schedule, Polyethylene Glycols, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, Internal medicine, Ribavirin, medicine, Humans, Prospective Studies, Rapid Virologic Response, genotype 1, Hepatology, business.industry, Standard treatment, Interferon-alpha, virus diseases, Hepatitis C, Middle Aged, medicine.disease, Recombinant Proteins, digestive system diseases, Confidence interval, Surgery, Treatment Outcome, chemistry, RNA, Viral, Drug Therapy, Combination, Female, hepatitis C, business
Abstract

It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n_696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, plus ribavirin, 1000-1200 mg/day, for 48 weeks (standard, n _237) or for 24, 48, or 72 weeks if HCV-RNA–negative at weeks 4, 8, or 12, respectively (variable, n _ 459). Sustained virologic response (SVR) was achieved in 45.1% [95% confidence interval (CI) 38.8-51.4] of the patients in the standard group and in 48.8% (CI 44.2-53.3) of the patients in the variable group (P _ 0.37). The percentages of patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12 were 26.7%, 27.8%, and 11.3%, respectively. In the standard treatment group, 87.1%, 70.3%, and 38.1% of patients who first achieved undetectable HCV RNA at 4, 8, or 12 weeks attained SVRs, respectively. In the variable group, corresponding SVR rates were 77.2%, 71.9%, and 63.5%. Low viremia levels and young age were independent predictors of response at week 4 [rapid virologic response (RVR)]. RVR patients with baseline viremia >400,000 IU/mL achieved higher SVR rates when treated for 48 weeks rather than 24 weeks (86.8% versus 73.1%, P _ 0.14). The only predictive factor of SVR in RVR patients was advanced fibrosis. Conclusion: Variable treatment duration ensures SVR rates similar to those of standard treatment duration, sparing unnecessary side effects and costs. (HEPATOLOGY 2008;47:43-50.)

Published
2008

42. Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth.

Author

Zamberlan M, Boeckx A, Muller F, Vinelli F, Ek O, Vianello C, Coart E, Shibata K, Christian A, Grespi F, Giacomello M, Struman I, Scorrano L, and Herkenne S

Subjects
Animals, Apoptosis, Cell Line, Tumor, Cell Proliferation, Disease Models, Animal, Female, Humans, Mice, Inbred NOD, Transfection, Triple Negative Breast Neoplasms pathology, Mice, GTP Phosphohydrolases metabolism, Mitochondrial Proteins metabolism, Triple Negative Breast Neoplasms genetics
Abstract

Background: Mitochondrial fusion and fission proteins have been nominated as druggable targets in cancer. Whether their inhibition is efficacious in triple negative breast cancer (TNBC) that almost invariably develops chemoresistance is unknown., Methods: We used a combination of bioinformatics analyses of cancer genomic databases, genetic and pharmacological Optic Atrophy 1 (OPA1) inhibition, mitochondrial function and morphology measurements, micro-RNA (miRNA) profiling and formal epistatic analyses to address the role of OPA1 in TNBC proliferation, migration, and invasion in vitro and in vivo., Results: We identified a signature of OPA1 upregulation in breast cancer that correlates with worse prognosis. Accordingly, OPA1 inhibition could reduce breast cancer cells proliferation, migration, and invasion in vitro and in vivo. Mechanistically, while OPA1 silencing did not reduce mitochondrial respiration, it increased levels of miRNAs of the 148/152 family known to inhibit tumor growth and invasiveness. Indeed, these miRNAs were epistatic to OPA1 in the regulation of TNBC cells growth and invasiveness., Conclusions: Our data show that targeted inhibition of the mitochondrial fusion protein OPA1 curtails TNBC growth and nominate OPA1 as a druggable target in TNBC., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

43. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.

Author

Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G, Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, and Andriulli A

Subjects
Drug Therapy, Combination, Female, Humans, Interferon alpha-2, Interferon-alpha therapeutic use, Italy, Male, Middle Aged, Polyethylene Glycols therapeutic use, Recombinant Proteins, Recurrence, Ribavirin therapeutic use, Time Factors, Viremia drug therapy, Antiviral Agents therapeutic use, Hepacivirus genetics, Hepatitis C, Chronic drug therapy
Abstract

Unlabelled: In hepatitis C virus (HCV) genotypes 2 and 3 patients, the high rate of relapse after 12 to 16 weeks of antiviral therapy is the main concern for shortening treatment duration. This study was undertaken to delineate predictors of relapse after short treatment in patients with undetectable HCV RNA at treatment week 4 (RVR), and to report in RVR patients with relapse the sustained virological response (SVR) after a second 24-week course of therapy. RVR patients received pegylated interferon (Peg-IFN) alfa-2b (1.5 microg/kg) and ribavirin (1000-1200 mg/day) for 12 weeks; those who relapsed were re-treated with the same drug doses but for the extended standard duration of 24 weeks. Logistic regression analysis was applied to delineate predictors of relapse by using age, sex, route of transmission, body mass index (BMI), serum alanine aminotransferase (ALT), HCV genotypes, serum HCV RNA levels, and platelet counts as covariates. Of 718 patients with genotypes 2 and 3 who were started on therapy, 496 (69.1%) had undetectable HCV RNA at week 4. Of them, 409 patients (82.5%, CI 79.1-85.8) attained SVR, and 67 (14.1%, CI 10.4-16.5) relapsed. At regression analysis, only platelet count less than 140,000 mm(3) [odds ratio, 2.51; confidence interval (CI), 1.49-4.20] and BMI 30 or higher (odds ratio, 1.7; CI, 1.03-2.70) were independently associated with relapse. Forty-three of 67 patients with relapse agreed to be re-treated, and an SVR was achieved in 30 (70.0%) of them., Conclusion: We recommend 12 weeks course of therapy for patients with undetectable HCV RNA at treatment week 4, providing they present with no advanced fibrosis and low BMI.

Published
2009
Full Text
View/download PDF

44. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.

Author

Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, and Andriulli A

Subjects
Adult, Antiviral Agents adverse effects, Drug Administration Schedule, Drug Therapy, Combination, Female, Genotype, Hepacivirus genetics, Humans, Interferon alpha-2, Interferon-alpha adverse effects, Male, Middle Aged, Polyethylene Glycols adverse effects, Prospective Studies, RNA, Viral blood, Recombinant Proteins, Ribavirin adverse effects, Treatment Outcome, Antiviral Agents administration & dosage, Hepacivirus drug effects, Hepatitis C drug therapy, Interferon-alpha administration & dosage, Polyethylene Glycols administration & dosage, Ribavirin administration & dosage
Abstract

Unlabelled: It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n = 696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, plus ribavirin, 1000-1200 mg/day, for 48 weeks (standard, n = 237) or for 24, 48, or 72 weeks if HCV-RNA-negative at weeks 4, 8, or 12, respectively (variable, n = 459). Sustained virologic response (SVR) was achieved in 45.1% [95% confidence interval (CI) 38.8-51.4] of the patients in the standard group and in 48.8% (CI 44.2-53.3) of the patients in the variable group (P = 0.37). The percentages of patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12 were 26.7%, 27.8%, and 11.3%, respectively. In the standard treatment group, 87.1%, 70.3%, and 38.1% of patients who first achieved undetectable HCV RNA at 4, 8, or 12 weeks attained SVRs, respectively. In the variable group, corresponding SVR rates were 77.2%, 71.9%, and 63.5%. Low viremia levels and young age were independent predictors of response at week 4 [rapid virologic response (RVR)]. RVR patients with baseline viremia >or=400,000 IU/mL achieved higher SVR rates when treated for 48 weeks rather than 24 weeks (86.8% versus 73.1%, P = 0.14). The only predictive factor of SVR in RVR patients was advanced fibrosis., Conclusion: Variable treatment duration ensures SVR rates similar to those of standard treatment duration, sparing unnecessary side effects and costs.

Published
2008
Full Text
View/download PDF

45. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study.

Author

Ascione A, De Luca M, Canestrini C, Di Costanzo GG, Raimondo G, Longo G, Manns MP, Tillmann HL, Forte GB, Rocco P, Biceglia O, Faleo D, Vinelli F, Cela EM, Amitrano L, Addario L, and Gigliotti T

Subjects
Adult, Aged, Alanine Transaminase blood, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Hepatitis C, Chronic complications, Hepatitis C, Chronic virology, Humans, Liver Cirrhosis enzymology, Liver Cirrhosis etiology, Male, Middle Aged, Prospective Studies, RNA, Viral analysis, Recombinant Proteins, Treatment Outcome, Antiviral Agents administration & dosage, Hepatitis C, Chronic drug therapy, Interferon Type I administration & dosage, Liver Cirrhosis drug therapy
Abstract

Background/aims: The long-term response to alpha-Interferon in HCV-related chronic liver diseases is disappointing. A randomized controlled trial was conducted to investigate: 1) if doubling the standard regimen of 3 MU recombinant alpha 2b-interferon thrice weekly for one year could improve the long-term response, and 2) the efficacy of these two schedules in cirrhotic patients., Patients and Methods: A series of 80 anti-HCV positive patients with biopsy proven liver disease (52 chronic hepatitis and 28 cirrhosis) were randomized to receive either 3 MU or 6 MU alpha 2b-interferon., Results: Based on "intention-to-treat analysis", 38% in the 3 MU group and 53% in the 6 MU group had end-of-treatment response. After 24 months, 18% had long-term response: 5% in 3 MU group and 30% in 6 MU group (p < 0.008). HCV genotype had no influence on the response rate. Thirty-eight percent of the cirrhotics treated with 6 MU had long-term response, while none of those treated with 3 MU had long-term response (difference 38%; 95% confidence internal 10%-67%; p = 0.03). At the end of treatment, 38% of patients lost HCV-RNA. After 24 months only 19% remained HCV-RNA negative: 12 patients (31%) in the 6 MU group and 2 (6%) in the 3 MU group (p < 0.05)., Conclusions: 6 MU of alpha 2b-interferon thrice weekly for 12 months is significantly better than 3 MU in inducing a long-term response and permanent loss of HCV-RNA. This result is particularly striking in the subgroup of cirrhotics.

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results